JP2009500455A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009500455A5 JP2009500455A5 JP2008521503A JP2008521503A JP2009500455A5 JP 2009500455 A5 JP2009500455 A5 JP 2009500455A5 JP 2008521503 A JP2008521503 A JP 2008521503A JP 2008521503 A JP2008521503 A JP 2008521503A JP 2009500455 A5 JP2009500455 A5 JP 2009500455A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- retinamide
- levels
- serum retinol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 30
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 22
- 210000002966 serum Anatomy 0.000 claims 12
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 11
- 229960003471 retinol Drugs 0.000 claims 11
- 235000020944 retinol Nutrition 0.000 claims 11
- 239000011607 retinol Substances 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 9
- 229940100552 retinamide Drugs 0.000 claims 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 5
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 4
- 238000002203 pretreatment Methods 0.000 claims 4
- AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 claims 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 230000007850 degeneration Effects 0.000 claims 3
- -1 elixirs Substances 0.000 claims 3
- 229950003662 fenretinide Drugs 0.000 claims 3
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 3
- 239000002207 metabolite Substances 0.000 claims 3
- 108091008695 photoreceptors Proteins 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- DBQHWMPFMCOGIW-GLKGMVBCSA-N (2z,4e,6z,8e)-n-(4-methoxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide Chemical compound C1=CC(OC)=CC=C1NC(=O)\C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C DBQHWMPFMCOGIW-GLKGMVBCSA-N 0.000 claims 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims 2
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 claims 2
- 241000208140 Acer Species 0.000 claims 2
- 206010003694 Atrophy Diseases 0.000 claims 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims 2
- 208000017442 Retinal disease Diseases 0.000 claims 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims 2
- 150000003973 alkyl amines Chemical class 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 235000006708 antioxidants Nutrition 0.000 claims 2
- 230000037444 atrophy Effects 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 235000021466 carotenoid Nutrition 0.000 claims 2
- 150000001747 carotenoids Chemical class 0.000 claims 2
- 239000002285 corn oil Substances 0.000 claims 2
- 235000005687 corn oil Nutrition 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 239000008298 dragée Substances 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 150000004665 fatty acids Chemical class 0.000 claims 2
- 239000000499 gel Substances 0.000 claims 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 2
- 239000000411 inducer Substances 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 239000002736 nonionic surfactant Substances 0.000 claims 2
- 150000003904 phospholipids Chemical class 0.000 claims 2
- 239000006187 pill Substances 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 235000021283 resveratrol Nutrition 0.000 claims 2
- 229940016667 resveratrol Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000002002 slurry Substances 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 239000006188 syrup Substances 0.000 claims 2
- 235000020357 syrup Nutrition 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- PJANXHGTPQOBST-VAWYXSNFSA-N trans-stilbene Chemical class C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 claims 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- 208000008069 Geographic Atrophy Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 101000665882 Homo sapiens Retinol-binding protein 4 Proteins 0.000 claims 1
- 101000772194 Homo sapiens Transthyretin Proteins 0.000 claims 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 claims 1
- 229940124761 MMP inhibitor Drugs 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 230000004300 dark adaptation Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 102000056556 human TTR Human genes 0.000 claims 1
- 229960005280 isotretinoin Drugs 0.000 claims 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 claims 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69851205P | 2005-07-11 | 2005-07-11 | |
| PCT/US2006/026770 WO2007008821A2 (en) | 2005-07-11 | 2006-07-10 | Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (rbp), and/or serum retinol-rbp modulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009500455A JP2009500455A (ja) | 2009-01-08 |
| JP2009500455A5 true JP2009500455A5 (https=) | 2009-07-02 |
Family
ID=36955418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008521503A Withdrawn JP2009500455A (ja) | 2005-07-11 | 2006-07-10 | 血清レチノール、血清レチノール結合タンパク質（ｒｂｐ）、および／または血清レチノール−ｒｂｐの調節によって眼科的状態を処置するための方法および組成物 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20070015827A1 (https=) |
| EP (1) | EP1904043A4 (https=) |
| JP (1) | JP2009500455A (https=) |
| KR (1) | KR20080055790A (https=) |
| CN (1) | CN101252924B (https=) |
| AR (1) | AR055075A1 (https=) |
| AU (1) | AU2006268374A1 (https=) |
| BR (1) | BRPI0612405A2 (https=) |
| CA (1) | CA2614627C (https=) |
| EA (1) | EA200800291A1 (https=) |
| GB (1) | GB2428975B (https=) |
| IL (1) | IL188528A0 (https=) |
| MX (1) | MX2008000064A (https=) |
| NO (1) | NO20080718L (https=) |
| TW (1) | TW200727894A (https=) |
| UA (1) | UA81382C2 (https=) |
| WO (1) | WO2007008821A2 (https=) |
| ZA (1) | ZA200800844B (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1768657T3 (pl) * | 2004-06-23 | 2009-01-30 | Revision Therapeutics Inc | Sposoby i kompozycje do leczenia stanów ocznych za pomocą pochodnych retinylowych |
| JP2008519054A (ja) * | 2004-11-04 | 2008-06-05 | シリオン セラピューティクス， インコーポレイテッド | レチノール−レチノール結合タンパク質（ｒｂｐ）−トランスチレチン（ｔｔｒ）複合体の形成のモジュレーター |
| CA2584845C (en) * | 2004-12-08 | 2009-02-17 | Sirion Therapeutics, Inc. | Methods, assays and compositions for treating retinol-related diseases |
| WO2009035673A1 (en) * | 2007-09-12 | 2009-03-19 | Trustees Of Columbia University In The City Of Newyork | Compositions and methods for treating macular degeneration |
| CN101229147B (zh) * | 2007-12-24 | 2010-09-01 | 复旦大学 | N-4-羟苯视黄酰胺在制备抗肝纤维化药物中的用途 |
| WO2009158027A1 (en) * | 2008-06-26 | 2009-12-30 | Cytosorbents, Inc. | Removal of myoglobin from blood and/or physiological fluids |
| JP5951625B2 (ja) * | 2010-11-24 | 2016-07-13 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨークＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｃｏｌｕｍｂｉａ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎ Ｔｈｅ Ｃｉｔｙ Ｏｆ Ｎｅｗ Ｙｏｒｋ | 加齢性黄斑変性症およびシュタルガルト病の処置のための非レチノイドｒｂｐ４アンタゴニスト |
| EP2648711A2 (en) * | 2010-12-06 | 2013-10-16 | ReVision Therapeutics, Inc. | Compositions and methods for treating ophthalmic conditions |
| WO2013166041A1 (en) * | 2012-05-01 | 2013-11-07 | The Trustees Of Columbia University In The City Of New York | Transthyretin ligands capable of inhibiting retinol-dependent rbp4-ttr interaction for treatment of age-related macular |
| US9333202B2 (en) | 2012-05-01 | 2016-05-10 | The Trustees Of Columbia University In The City Of New York | Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease |
| US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
| US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
| WO2014152018A1 (en) | 2013-03-14 | 2014-09-25 | The Trustees Of Columbia University In The City Of New York | Octahydrocyclopentapyrroles, their preparation and use |
| EP3495357B1 (en) | 2013-03-14 | 2021-05-05 | The Trustees of Columbia University in the City of New York | 4-phenylpiperidines, their preparation and use |
| US10092393B2 (en) | 2013-03-14 | 2018-10-09 | Allotex, Inc. | Corneal implant systems and methods |
| US9944644B2 (en) | 2013-03-14 | 2018-04-17 | The Trustees Of Columbia University In The City Of New York | Octahydropyrrolopyrroles their preparation and use |
| US9938291B2 (en) | 2013-03-14 | 2018-04-10 | The Trustess Of Columbia University In The City Of New York | N-alkyl-2-phenoxyethanamines, their preparation and use |
| ES3012058T3 (en) * | 2014-02-13 | 2025-04-08 | Katairo Gmbh | Compounds for the treatment of lipofuscin related diseases |
| SG11201608943VA (en) | 2014-04-30 | 2016-11-29 | Univ Columbia | Substituted 4-phenylpiperidines, their preparaiton and use |
| US10449090B2 (en) | 2015-07-31 | 2019-10-22 | Allotex, Inc. | Corneal implant systems and methods |
| CN108602868B (zh) * | 2016-01-25 | 2022-12-30 | 伯尔尼大学 | Sec14样蛋白及同源配体的纳米球 |
| GB201706009D0 (en) * | 2017-04-13 | 2017-05-31 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of stargardt disease |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2004A (en) * | 1841-03-12 | Improvement in the manner of constructing and propelling steam-vessels | ||
| US4190594A (en) * | 1975-11-03 | 1980-02-26 | Johnson & Johnson | Retinoic acid derivatives |
| US4323581A (en) * | 1978-07-31 | 1982-04-06 | Johnson & Johnson | Method of treating carcinogenesis |
| US4665098A (en) * | 1985-03-28 | 1987-05-12 | Mcneilab, Inc. | Pharmaceutical composition of N-(4-hydroxyphenyl) retinamide having increased bioavailability |
| US4874795A (en) * | 1985-04-02 | 1989-10-17 | Yesair David W | Composition for delivery of orally administered drugs and other substances |
| US5023252A (en) * | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4743400A (en) * | 1986-09-22 | 1988-05-10 | Mcneilab, Inc. | Process for preparing retinoyl chlorides |
| US5814612A (en) * | 1991-04-09 | 1998-09-29 | Sloan-Kettering Institute For Cancer Research | Retinol derivatives and uses thereof |
| US6506917B1 (en) * | 1991-12-18 | 2003-01-14 | The Salk Institute For Biological Studies | Compounds and compositions useful for modulation of processes mediated by RXR |
| US6093706A (en) * | 1992-03-04 | 2000-07-25 | Bioresponse, L.L.C. | Combined dehydroepiandrosterone and retinoid therapy for epithelial disorders |
| US5314909A (en) * | 1993-03-17 | 1994-05-24 | Merck & Co., Inc. | Use of non-steroidal antiiflammatory agents in macular degeneration |
| US5399757A (en) * | 1993-07-20 | 1995-03-21 | Ortho Pharmaceutical Corporation | Process for the preparation of N-(4-hydroxyphenyl)-retinamide |
| US5427571A (en) * | 1994-08-08 | 1995-06-27 | Cor-A-Vent Incorporated | Ventilated cap system for the ridge of a roof |
| US5824685A (en) * | 1995-02-01 | 1998-10-20 | The Johns Hopkins University School Of Medicine | Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists |
| US5596011A (en) * | 1995-04-06 | 1997-01-21 | Repine; Karen M. | Method for the treatment of macular degeneration |
| US5846220A (en) * | 1996-04-30 | 1998-12-08 | Medtronic, Inc. | Therapeutic method for treatment of Alzheimer's disease |
| US6034211A (en) * | 1996-06-03 | 2000-03-07 | Kelly; Jeffery W. | β-sheet nucleating peptidomimetics |
| US5955305A (en) * | 1997-04-28 | 1999-09-21 | Incyte Pharmaceuticals, Inc. | Human retinoid binding protein |
| US5776915A (en) * | 1997-08-12 | 1998-07-07 | Clarion Pharmaceuticals Inc. | Phosphocholines of retinoids |
| DE69840126D1 (de) * | 1997-08-15 | 2008-11-27 | Univ Duke | Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten |
| AU3980499A (en) * | 1998-05-11 | 1999-11-29 | Endowment for Research in Human Biology, Inc., The | Use of neomycin for treating angiogenesis-related diseases |
| EP1153248B1 (en) * | 1998-12-17 | 2006-04-19 | Diversi-Plast Products Inc. | Ridge cap vent |
| US6128870A (en) * | 1999-05-24 | 2000-10-10 | Kohler; Raymond L. | Roof vent system |
| US7229961B2 (en) * | 1999-08-24 | 2007-06-12 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into ocular tissues |
| US20020031539A1 (en) * | 2000-08-30 | 2002-03-14 | The Brigham And Women's Hospital, Inc. | Oxidized forms of retinoic acid as ligands for peroxisome proliferator activated receptor gamma |
| US6450882B1 (en) * | 2000-08-30 | 2002-09-17 | Liberty Diversified Industries, Inc. | Precipitation resistant ridge vent |
| WO2002032413A2 (en) * | 2000-10-17 | 2002-04-25 | Board Of Regents, The University Of Texas System | A method to incorporate n-(4-hydroxyphenyl) retinamide in liposomes |
| JP4384409B2 (ja) * | 2000-12-05 | 2009-12-16 | チルドレンズ・ホスピタル・ロス・アンジエルス | バイオアベイラビリティが増加したフェンレチニドの医薬組成物、およびその使用方法 |
| US20030032078A1 (en) * | 2001-01-23 | 2003-02-13 | Board Of Regents, The University Of Texas System | Methods and compositions for the treatment of macular and retinal degenerations |
| EP1408814A4 (en) * | 2001-06-15 | 2004-10-20 | Cleveland Clinic Foundation | RATIOMETRIC QUANTIFICATION OF THE TRIGGERED AUTOFLUORESCENCE ON THE EYE |
| CA2450562A1 (en) * | 2001-06-22 | 2003-01-03 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| AU2002316593A1 (en) * | 2001-07-06 | 2003-01-21 | The Ohio State University Research Foundation | Solid phase synthesis of arylretinamides |
| WO2003007944A1 (en) * | 2001-07-20 | 2003-01-30 | Qlt, Inc. | Treatment of macular edema with photodynamic therapy |
| WO2004041160A2 (en) * | 2002-10-30 | 2004-05-21 | University Of Kentucky Research Foundation | Methods and animal model for analyzing age-related macular degeneration |
| US7354574B2 (en) * | 2002-11-07 | 2008-04-08 | Advanced Ocular Systems Limited | Treatment of ocular disease |
| US20080176952A1 (en) * | 2004-02-17 | 2008-07-24 | Rando Robert R | Management of Ophthalmologic Disorders, Including Macular Degeneration |
| US7566808B2 (en) * | 2004-02-17 | 2009-07-28 | President And Fellows Of Harvard College | Management of ophthalmologic disorders, including macular degeneration |
| PL1768657T3 (pl) * | 2004-06-23 | 2009-01-30 | Revision Therapeutics Inc | Sposoby i kompozycje do leczenia stanów ocznych za pomocą pochodnych retinylowych |
| AU2005287343A1 (en) * | 2004-08-18 | 2006-03-30 | Sirion Therapeutics, Inc. | Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders |
| JP2008519054A (ja) * | 2004-11-04 | 2008-06-05 | シリオン セラピューティクス， インコーポレイテッド | レチノール−レチノール結合タンパク質（ｒｂｐ）−トランスチレチン（ｔｔｒ）複合体の形成のモジュレーター |
| CA2584845C (en) * | 2004-12-08 | 2009-02-17 | Sirion Therapeutics, Inc. | Methods, assays and compositions for treating retinol-related diseases |
-
2005
- 2005-07-12 UA UAA200704499A patent/UA81382C2/uk unknown
-
2006
- 2006-07-10 JP JP2008521503A patent/JP2009500455A/ja not_active Withdrawn
- 2006-07-10 KR KR1020087003028A patent/KR20080055790A/ko not_active Ceased
- 2006-07-10 ZA ZA200800844A patent/ZA200800844B/xx unknown
- 2006-07-10 EP EP06800032A patent/EP1904043A4/en not_active Withdrawn
- 2006-07-10 CA CA2614627A patent/CA2614627C/en not_active Expired - Fee Related
- 2006-07-10 WO PCT/US2006/026770 patent/WO2007008821A2/en not_active Ceased
- 2006-07-10 EA EA200800291A patent/EA200800291A1/ru unknown
- 2006-07-10 BR BRPI0612405-4A patent/BRPI0612405A2/pt not_active IP Right Cessation
- 2006-07-10 US US11/484,228 patent/US20070015827A1/en not_active Abandoned
- 2006-07-10 AU AU2006268374A patent/AU2006268374A1/en not_active Abandoned
- 2006-07-10 MX MX2008000064A patent/MX2008000064A/es not_active Application Discontinuation
- 2006-07-10 CN CN2006800312331A patent/CN101252924B/zh not_active Expired - Fee Related
- 2006-07-11 TW TW095125338A patent/TW200727894A/zh unknown
- 2006-07-11 GB GB0613730A patent/GB2428975B/en not_active Expired - Fee Related
- 2006-07-11 AR ARP060102980A patent/AR055075A1/es not_active Application Discontinuation
-
2008
- 2008-01-01 IL IL188528A patent/IL188528A0/en unknown
- 2008-02-08 NO NO20080718A patent/NO20080718L/no not_active Application Discontinuation
-
2012
- 2012-05-17 US US13/474,582 patent/US20120288568A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009500455A5 (https=) | ||
| WO2007093624A2 (en) | Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin | |
| JP2010077141A5 (https=) | ||
| JP2008504257A5 (https=) | ||
| JP2015523546A5 (https=) | ||
| JP2008515778A5 (https=) | ||
| JP2004307506A5 (https=) | ||
| RU2011103741A (ru) | Композиции и способы лечения заболевания сетчатки | |
| CA2521325A1 (en) | Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol | |
| CO6160301A2 (es) | Preparacion solida que contiene alogliptina y clorhidrato de metformina | |
| CA2569691A1 (en) | Methods and compositions for treating ophthalmic conditions with retinyl derivatives | |
| JP2014505017A5 (https=) | ||
| JP2008521827A5 (https=) | ||
| JP2012508734A5 (https=) | ||
| JP2011514384A (ja) | 望ましい生物学的利用能を有する薬学的組成物 | |
| JP2013500977A5 (https=) | ||
| JP2022519131A5 (https=) | ||
| MA34897B1 (fr) | Formulations d'immunosupresseurs | |
| JP2013519653A5 (https=) | ||
| MA34806B1 (fr) | Compositions pharmaceutiques | |
| JP2017508817A5 (https=) | ||
| WO2019046287A1 (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HEPATITIS B | |
| JP2007515467A5 (https=) | ||
| NO20082181L (no) | Formuleringer av Fispemifen | |
| CA2677842A1 (en) | Pharmaceutical composition comprising microparticle oily suspension |